MLN 608

Drug Profile

MLN 608

Alternative Names: MLN608

Latest Information Update: 08 Jun 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Millennium Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Glioblastoma

Most Recent Events

  • 08 Jun 2006 No development reported - Preclinical for Glioblastoma in USA (unspecified route)
  • 19 Feb 2003 Preclinical trials in Glioblastoma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top